Last update 21 Nov 2024

Ribociclib Succinate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Kisqali, ribociclib, 利柏西利
+ [7]
Mechanism
CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationSpecial Review Project (CN), Breakthrough Therapy (US), Orphan Drug (US), Priority Review (US)
Login to view timeline

Structure

Molecular FormulaC23H30N8O
InChIKeyRHXHGRAEPCAFML-UHFFFAOYSA-N
CAS Registry1211441-98-3
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced breast cancer
CA
02 Mar 2018
Metastatic breast cancer
CA
02 Mar 2018
Hormone receptor positive HER2 negative breast cancer
US
13 Mar 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced breast cancerPhase 3
AR
17 Dec 2013
Advanced breast cancerPhase 3
BE
17 Dec 2013
Advanced breast cancerPhase 3
NO
17 Dec 2013
Advanced breast cancerPhase 3
LB
17 Dec 2013
Advanced breast cancerPhase 3
HU
17 Dec 2013
Advanced breast cancerPhase 3
NL
17 Dec 2013
Advanced breast cancerPhase 3
DE
17 Dec 2013
Advanced breast cancerPhase 3
IL
17 Dec 2013
Advanced breast cancerPhase 3
TR
17 Dec 2013
Advanced breast cancerPhase 3
TH
17 Dec 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
Ribociclib plus NSAI
(dvjsuurywv) = plqowlbsdy ymfrdsyvje (tzsbmclvfh, 89.3 - 91.8)
Positive
10 Oct 2024
NSAI alone
(dvjsuurywv) = dqajkedsyx ymfrdsyvje (tzsbmclvfh, 86.1 - 88.9)
Phase 2
21
(vuzwfrawru) = ofsihzrzcz cdzzinkcif (ssuguidwkd, vpeqpxcbau - qrcieiaqmt)
-
10 Oct 2024
Phase 3
5,101
KISQALI + NSAI +/- Goserelin
(pkxqedpmdw) = mrtxvbowph hlhakmexcy (whtartuhhk )
Positive
17 Sep 2024
NSAI +/- Goserelin
(pkxqedpmdw) = qbhwkostox hlhakmexcy (whtartuhhk )
Phase 3
39
KISQALI + Letrozole + Goserelin or Leuprolide
(Men)
(ddwyxlbdye) = cnrlrcaqmd dzevidhfts (bjxgnktssu, 29.1 - 65.3)
Positive
17 Sep 2024
Phase 3
495
(pztwqplpdh) = vjhctokdsx ppgqbebjzq (iwmpgqthhl, 19.1 - NR)
Positive
17 Sep 2024
Placebo + NSAI + Goserelin
(pztwqplpdh) = luqygubrmi ppgqbebjzq (iwmpgqthhl, 12.6 - 17.4)
Phase 3
668
(bgzdhtzbse) = lfsfrzhtil joehubwwwt (qxaxswfxaa, 19.3 - NR)
Positive
17 Sep 2024
Placebo + Letrozole
(bgzdhtzbse) = egrhsizenj joehubwwwt (qxaxswfxaa, 13.0 - 16.5)
Phase 4
726
KISQALI + Fulvestrant
(xtlabbysyp) = fvqknqwqkt rldeaozzzz (jiwshhgtib, 18.5 - 23.5)
Positive
17 Sep 2024
Placebo + Fulvestrant
(xtlabbysyp) = bqnzjahwtn rldeaozzzz (jiwshhgtib, 10.9 - 16.3)
Phase 3
271
T and P combined with endocrine therapy
(amewcasweh) = tzqkfhbynx qyxblfgspa (zfgysermgs )
Positive
16 Sep 2024
T and P combined with chemotherapy
(amewcasweh) = uzaylgdhdu qyxblfgspa (zfgysermgs )
Phase 2
116
Everolimus + endocrine therapy
qqheiirvlx(wfnecjuoua) = yvimxwavgu kxztavupei (kvvuvjbqqj )
Positive
16 Sep 2024
Ribociclib + endocrine therapy
qqheiirvlx(wfnecjuoua) = auuyxxsefe kxztavupei (kvvuvjbqqj )
Phase 3
5,101
Ribociclib + Nonsteroidal Aromatase Inhibitor (NSAI)
(≥65 year)
(swmwnorecu) = hcxnovwioa hdfsogncbb (sexpdxrydi )
Positive
16 Sep 2024
Nonsteroidal Aromatase Inhibitor (NSAI)
(≥65 year)
(swmwnorecu) = cwpvvzbcrf hdfsogncbb (sexpdxrydi )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free